HCW Biologics reports Phase 1 signal for IL-2 fusion drug in alopecia
HCW Biologics has released preliminary Phase 1 data for HCW9302, its IL-2 based fusion immunotherapeutic, in patients with alopecia areata. All three participants in the second dose cohort, who received a single subcutaneous injection of three micrograms per kilogram of body weight, showed a reduction of at least 25% in Severity of Alopecia Tool (SALT) scores relative to baseline at four and/or nine weeks after dosing. The NASDAQ-listed company described the readout as "highly encouraging" and said it remains on track to determine a Recommended Phase 2 Dose by the end of 2026.
The trial is a multi-centre, dose-escalating Phase 1 study designed to enrol up to 30 patients with alopecia areata across two active sites in the United States: The Ohio State University Wexner Medical Center and the James A. Haley Veterans' Hospital in Tampa. The three participants in the second cohort all had mild disease. The company has now moved to a third dose cohort at eight micrograms per kilogram, with dosing under way and correlative endpoint evaluation ongoing.
Safety profile
The safety data accompanying this readout is arguably as significant as the efficacy signal, given that conventional IL-2 therapies carry a well-documented burden of serious side effects. No dose-limiting toxicities were observed across either dose cohort. There were no incidences of capillary leak syndrome or cytokine release syndrome, both associated with high-dose intravenous IL-2. HCW9302 also did not increase blood eosinophil counts, another common adverse event with IL-2 treatments. Reported side effects were mild, self-limiting, and required no medical intervention; the most common was a temporary injection-site reaction.
HCW Biologics attributes this profile to HCW9302's strong bias towards the IL-2 receptor alpha chain expressed on regulatory T cells, which the company argues allows preferential expansion of Tregs without broadly activating immune effector cells. Founder and chief executive Hing C. Wong described the molecule as differentiated from both native recombinant IL-2 and IL-2 muteins and PEG conjugates, noting it is constructed from entirely human-derived components and manufactured through a process comparable to therapeutic monoclonal antibodies.
Market context and competitive landscape
Alopecia areata is an area that has recently attracted significant commercial attention. Pfizer's ritlecitinib and Eli Lilly's baricitinib, both JAK inhibitors, are approved in the indication, and several other JAK and TYK2 inhibitors are in late-stage development. The IL-2 and Treg-expansion approach represents a mechanistically distinct strategy, one that targets upstream immune dysregulation rather than downstream inflammatory signalling.
The broader IL-2 therapy landscape is competitive. Companies including Syndax Pharmaceuticals, Sanofi and a number of university spinouts are pursuing engineered IL-2 or IL-2 receptor-selective variants for autoimmune and oncology settings. HCW Biologics' IL-2Rα bias claim, if it holds through dose escalation and multi-dose studies, could represent a differentiating feature, but the Phase 1 data is early, based on a small number of patients with mild disease, and single-dose results in alopecia will need to be replicated in larger, multi-dose cohorts before any comparative conclusions are warranted.
Looking further out, the company has flagged intent to explore HCW9302 in vitiligo, atopic dermatitis, and, notably, amyotrophic lateral sclerosis, citing recently published clinical evidence linking Treg and IL-2 treatment to potential benefit in ALS. That ambition adds pipeline optionality but also execution risk for a clinical-stage company. Near-term focus remains on completing dose escalation and setting the Phase 2 dose, expected before the end of this year.